Noel J. Cusack, Ph.D.

Affiliations: 
Boston Life Sciences, Inc. 
Area:
Purines
Google:
"Noel Cusack"
Mean distance: 20.21 (cluster 56)
 
Cross-listing: Neurotree

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Cusack NJ, Hourani SM. (2000) Platelet P2 receptors: from curiosity to clinical targets. Journal of the Autonomic Nervous System. 81: 37-43
Hourani SMO, Welford LA, Cusack NJ. (1996) Effects of 2-methylthioadenosine 5'-β,γ-methylenetriphosphonate and 2-ethylthioadenosine 5'-monophosphate on human platelet activation induced by adenosine 5'-diphosphate Drug Development Research. 38: 12-23
Cusack NJ, Pettey CJ. (1996) Effects of phosphate-modified analogs of adenosine 5'-diphosphate and adenosine 5'-triphosphate at P(2T)-purinoceptors mediating human platelet activation by ADP Drug Development Research. 37: 212-222
Martin PL, Gero TW, Potts AA, et al. (1995) Structure-activity studies of analogs of β,γ-methylene-ATP at P(2x)-Purinoceptors in the rabbit ear central artery Drug Development Research. 36: 153-165
Martin PL, Kelly M, Cusack NJ. (1993) (-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0923), a selective D2 dopamine receptor agonist demonstrates the presence of D2 dopamine receptors in the mouse vas deferens but not in the rat vas deferens. The Journal of Pharmacology and Experimental Therapeutics. 267: 1342-8
Cusack NJ. (1993) P2 receptor: Subclassification and structure-activity relationships Drug Development Research. 28: 244-252
Peck JV, Cusack NJ. (1993) N-0861. Adenosine A1 antagonist Drugs of the Future. 18: 433-435
Cusack NJ, Peck JV. (1993) N-0923. Dopamine D2 agonist Drugs of the Future. 18: 1005-1008
Hourani SM, Cusack NJ. (1991) Pharmacological receptors on blood platelets. Pharmacological Reviews. 43: 243-98
Cusack NJ, Hourani SM. (1990) Subtypes of P2-purinoceptors. Studies using analogues of ATP. Annals of the New York Academy of Sciences. 603: 172-81
See more...